BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943

Reuters

04 Dec 2024

BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943

Dec 4 (Reuters) - Vincerx Pharma VINC.O:

VINCERX PHARMA TO IMPLEMENT COST-CONTROLS TO SUPPORT ADVANCING PHASE 1 STUDY OF VIP943
VINCERX PHARMA INC: WILL BEGIN EXPLORING STRATEGIC ALTERNATIVES TO COMPLEMENT ONGOING FUNDRAISING EFFORTS
VINCERX PHARMA INC: AS OF OCTOBER 31, 2024, COMPANY HAD APPROXIMATELY $8.4 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES
VINCERX PHARMA INC: TO STREAMLINE OPERATIONS AND FOCUS RESOURCES, VINCERX WILL IMPLEMENT A SIGNIFICANT REDUCTION IN FORCE OF APPROXIMATELY 55%

Source text: ID:nGNX476253

Further company coverage: VINC.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488768164"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488768164\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2488768164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488768164","market":"us","top_or_hot":-1,"title":"BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Vincerx Pharma <span>VINC.O</span>:</p><ul><li><p>VINCERX PHARMA TO IMPLEMENT COST-CONTROLS TO SUPPORT ADVANCING PHASE 1 STUDY OF VIP943</p></li><li><p>VINCERX PHARMA INC: WILL BEGIN EXPLORING STRATEGIC ALTERNATIVES TO COMPLEMENT ONGOING FUNDRAISING EFFORTS</p></li><li><p>VINCERX PHARMA INC: AS OF OCTOBER 31, 2024, COMPANY HAD APPROXIMATELY $8.4 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES</p></li><li><p>VINCERX PHARMA INC: TO STREAMLINE OPERATIONS AND FOCUS RESOURCES, VINCERX WILL IMPLEMENT A SIGNIFICANT REDUCTION IN FORCE OF APPROXIMATELY 55%</p></li></ul><p>Source text: <span>ID:nGNX476253</span></p><p>Further company coverage: <span>VINC.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-04 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Vincerx Pharma <span>VINC.O</span>:</p><ul><li><p>VINCERX PHARMA TO IMPLEMENT COST-CONTROLS TO SUPPORT ADVANCING PHASE 1 STUDY OF VIP943</p></li><li><p>VINCERX PHARMA INC: WILL BEGIN EXPLORING STRATEGIC ALTERNATIVES TO COMPLEMENT ONGOING FUNDRAISING EFFORTS</p></li><li><p>VINCERX PHARMA INC: AS OF OCTOBER 31, 2024, COMPANY HAD APPROXIMATELY $8.4 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES</p></li><li><p>VINCERX PHARMA INC: TO STREAMLINE OPERATIONS AND FOCUS RESOURCES, VINCERX WILL IMPLEMENT A SIGNIFICANT REDUCTION IN FORCE OF APPROXIMATELY 55%</p></li></ul><p>Source text: <span>ID:nGNX476253</span></p><p>Further company coverage: <span>VINC.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VINC","symbol_name":"Vincera Pharma, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N513Q:1","article_id":"2488768164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488768164","pubTimestamp":1733313480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943Dec 4 (Reuters) - Vincerx Pharma VINC.O:VINCERX PHARMA TO IMPLEMENT COST-CONTROLS TO SUPPORT ADVANCING PHASE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VINC":"Vincera Pharma, Inc.","BK4139":"生物科技"},"translate_title":"简介-Vincerx Pharma将实施成本控制以支持推进VIP943的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VINC":0.9},"content_text":"BRIEF-Vincerx Pharma To Implement Cost-Controls To Support Advancing Phase 1 Study Of VIP943Dec 4 (Reuters) - Vincerx Pharma VINC.O:VINCERX PHARMA TO IMPLEMENT COST-CONTROLS TO SUPPORT ADVANCING PHASE 1 STUDY OF VIP943VINCERX PHARMA INC: WILL BEGIN EXPLORING STRATEGIC ALTERNATIVES TO COMPLEMENT ONGOING FUNDRAISING EFFORTSVINCERX PHARMA INC: AS OF OCTOBER 31, 2024, COMPANY HAD APPROXIMATELY $8.4 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIESVINCERX PHARMA INC: TO STREAMLINE OPERATIONS AND FOCUS RESOURCES, VINCERX WILL IMPLEMENT A SIGNIFICANT REDUCTION IN FORCE OF APPROXIMATELY 55%Source text: ID:nGNX476253Further company coverage: VINC.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}